Skip to main content
SpringerLink
Log in

Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

C-reactive protein (CRP) is known to be associated with poor prognosis in patients with various malignancies. We investigated the relationship between the pretreatment serum CRP level and survival in patients with hepatocellular carcinoma (HCC) in various stages of the disease. A cohort of 133 patients with newly diagnosed HCC was prospectively evaluated. The patients were divided into two groups: high-CRP group (n = 27) with the pretreatment serum CRP level ≧ 1.0 mg/dl and low-CRP group (n = 106) with the CRP level < 1.0 mg/dl. They were followed 22 months in average (1–69 months) and clinicopathological variables, and overall survivals between the two groups were compared at the end of the follow-up period. There was a significant difference between the two groups in aspartate aminotransferase, alanine aminotransferase, total serum bilirubin, albumin, α-fetoprotein level, maximal tumor diameter, frequency of vascular invasion and extrahepatic metastases. Patients in the high-CRP group had higher Child-Pugh scores, higher Cancer of the Liver Italian Program scores and higher Japan Integrated Staging scores than patients in the low-CRP group. The overall survival rates in the high-CRP group were significantly lower than those in the low-CRP group. Survival rates were similar in tumor stage and liver function-matched patients. On multivariate analysis, pretreatment serum CRP level was independently associated with overall survival. Our results demonstrate that the pretreatment serum CRP level is associated with tumor progression and reduced liver function and is an independent poor prognostic marker in patients with HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448–58.

    Article  PubMed  Google Scholar 

  2. Stiff GM, Gomez D, Prasad KR. C-reactive protein in liver cancer surgery. Eur J Surg Oncol. 2008;34:727–9.

    Article  Google Scholar 

  3. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197–201.

    Article  PubMed  CAS  Google Scholar 

  4. Rashid SA, Quigley JO, Axon ATR, Cooper EH. Plasma protein profiles and prognosis in gastric cancer. Br J Cancer. 1982;45:390–4.

    Article  PubMed  CAS  Google Scholar 

  5. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176:335–8.

    Article  PubMed  CAS  Google Scholar 

  6. McMillan DC, Canna K, McArdlle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90:215–9.

    Article  PubMed  CAS  Google Scholar 

  7. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology. 2000;59:296–301.

    Article  PubMed  CAS  Google Scholar 

  8. Scott HR, McMillan DC, Forrest LM, Brown DJF, McArdlle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 2002;87:264–7.

    Article  PubMed  CAS  Google Scholar 

  9. Fujikawa K, Matsui Y, Oka H, Fukuzawa S, Takeuchi H. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol. 1999;162:1934–7.

    Article  PubMed  CAS  Google Scholar 

  10. Pierce BL, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437–44.

    Article  PubMed  CAS  Google Scholar 

  11. Kodama J, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999;82:107–10.

    Article  PubMed  CAS  Google Scholar 

  12. Hashimoto K, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856–64.

    Article  PubMed  CAS  Google Scholar 

  13. Nagaoka S, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27:1091–7.

    Article  PubMed  CAS  Google Scholar 

  14. Tokushige K, et al. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010;45:960–7.

    Article  PubMed  CAS  Google Scholar 

  15. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma. Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909–22.

    Article  PubMed  Google Scholar 

  16. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462–503.

    Article  PubMed  CAS  Google Scholar 

  17. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28:751–5.

    Article  Google Scholar 

  18. Kudo M, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396–405.

    Article  PubMed  Google Scholar 

  19. Makuuchi M, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38:37–51.

    Article  PubMed  Google Scholar 

  20. Heikkila K, Eblahim S, Lawlor D. A systematic review of the association between circulating concentrations of C-reactive protein and cancer. J Epidemiol Community Health. 2007;61:824–32.

    Article  PubMed  Google Scholar 

  21. Legouffe E, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin’s lymphoma. Leukemia Lymphoma. 1998;31:351–7.

    PubMed  CAS  Google Scholar 

  22. Chun JM, et al. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol. 2011;103:148–51.

    Article  PubMed  Google Scholar 

  23. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.

    Article  PubMed  Google Scholar 

  24. Pawlic TM, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg. 2005;140:450–8.

    Article  Google Scholar 

  25. Nathan H, Schulick RD, Choti MA, Pawlic TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799–805.

    Article  PubMed  Google Scholar 

  26. Sakata H, et al. Prognostic factors for hepatocellular carcinoma presenting with macroscopic portal vein tumor thrombus. Hepatogastroenterology. 2004;51:1575–80.

    PubMed  Google Scholar 

  27. Pinter M, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther. 2011;34:949–59.

    Article  PubMed  CAS  Google Scholar 

  28. Huitzil-Melendez FD, et al. Advanced hepatocellular carcinoma: which staging system best predict prognosis? J Clin Oncol. 2010;28:2889–95.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors disclose no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, Komae-shi, Tokyo, 201-8601, Japan

    Akiyoshi Kinoshita, Hiroshi Onoda, Keiko Takano, Nami Imai, Chisato Saeki, Nao Fushiya, Yoshinari Miyakawa & Hirokazu Nishino

  2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, 105-0003, Japan

    Hisao Tajiri

Authors
  1. Akiyoshi Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Onoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keiko Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nami Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chisato Saeki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nao Fushiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshinari Miyakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hirokazu Nishino
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hisao Tajiri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akiyoshi Kinoshita.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kinoshita, A., Onoda, H., Takano, K. et al. Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Med Oncol 29, 2800–2808 (2012). https://doi.org/10.1007/s12032-012-0220-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-012-0220-1

Keywords

Search

Navigation